Viscum album extracts Iscador®P and Iscador®M counteract the growth factor induced effects in human follicular B-NHL cells and breast cancer cells

Medicina

Volumn 67, Issue SUPPL. 2, 2007, Pages 90-96

  Hugo, Frauke ^a   Schwitalla, Sarah ^a   Niggemann, Bernd ^a   Zänker, Kurt S ^a   Dittmar, Thomas ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Breast cancer; Cell movement; Follicular B Non Hodgkin's Lymphoma; Growth factor; Proliferation; Viscum album extracts

Indexed keywords

EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; INTERLEUKIN 6; PROTEIN BAX; PROTEIN BCL 2; VISCUM ALBUM EXTRACT;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENCY; GERMANY; HUMAN; HUMAN CELL; INHIBITION KINETICS; NONHODGKIN LYMPHOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VISCUM ALBUM;

EID: 34548483703     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Heyder C, Gloria-Maercker E, Hatzmann W, Niggemann B, Zanker KS, Dittmar T. Role of the beta1-integrin subunit in the adhesion, extravasation and migration of T24 human bladder carcinoma cells. Clin Exp Metastasis 2005; 22: 99-106.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Weis J, Bartsch H, Hennies F, et al. Complementary Medicine in Cancer Patients: Demand, Patient's Attitudes and Physiological Beliefs. Onkologie 1998; 144-9.
4. Hugo F, Dittmar T, Treutler EK, Zanker KS, Kuehn JJ. The Viscum album extract Iscador P does not cause an autocrine interleukin-6 loop in B-Non-Hodgkin's Lymphoma cell lines. Onkologie 2005; 28: 415-20.
5. Piao BK, Wang YX, Xie GR, et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 2004; 24: 303-9.
6. Stein G, Henn W, von Laue H, Berg P. Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy. Eur J Med Res 1998; 3: 194-202.
7. Stein GM, Berg PA. Modulation of cellular and humoral immune responses during exposure of healthy individuals to an aqueous mistletoe extract. Eur J Med Res 1998; 3: 307-14.
8. Rose-John S. Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol 2003; 50: 603-11.
9. Kurzrock R. Cytokine deregulation in hematological malignancies: clinical and biological implications. Clin Cancer Res 1997; 3: 2581-4.
10. Kato H, Kinoshita T, Suzuki S, et al. Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1998; 29: 71-9.
11. Dittmar T, Husemann A, Schewe Y, et al. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. Faseb J 2002; 16: 1823-5.
12. Grossarth-Maticek R, Ziegler R. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res 2006; 11: 485-95.
13. Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Forsch Komplementarmed 2006; 13: 285-92.
14. Dittmar T, Schafer F, Brandt BH, Zänker KS. Accelerated assessing of antisense RNA efficacy using a chimeric enhanced green fluorescent protein-antisense RNA-producing vector. Antisense Nucleic Acid Drug Dev 2000; 10: 401-8.
15. Katterle Y, Brandt BH, Dowdy SF, Niggemann B, Zanker KS, Dittmar T. Antitumour effects of PLC-gamma1-(SH2)2-TAT fusion proteins on EGFR/ c-erbB-2-positive breast cancer cells. Br J Cancer 2004; 90: 230-5.
16. Brandt BH, Roetger A, Dittmar T, et al. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. Faseb J 1999; 13: 1939-49.
17. Dittmar T, Brandt BH, Lang K, Zaenker KS, Entschladen F. Lessons from tumor and immunocompetent cells. The quantitative engagement of ligand-receptor interactions modulates stop-and-go behavior as well as proliferation. Medicina (Buenos Aires) 2000; 60 Suppl 2: 27-33.
18. Kovacs E, Kuehn JJ. Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does viscum album treatment affect these parameters? Biomed Pharmacother 2002; 56: 152-8.